Results 181 to 190 of about 59,855 (258)
Treatment Recommendations for Tardive Dyskinesia
Canadian Journal of Psychiatry, 2019 Background: Tardive dyskinesia is a movement disorder characterised by irregular, stereotyped, and choreiform movements associated with the use of antipsychotic medication. We aim to provide recommendations on the treatment of tardive dyskinesia. Methods:
Tamara Pringsheim +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Annual Review of Medicine, 1984
Although there are many published studies on the treatment of tardive dyskinesia (TD), relatively few treatments have proven to be consistently useful in clinical practice. Reviewed critically, most treatments have produced only slight to moderate benefit in less than half the patients treated.
C G, Goetz, H L, Klawans
+7 more sources
Although there are many published studies on the treatment of tardive dyskinesia (TD), relatively few treatments have proven to be consistently useful in clinical practice. Reviewed critically, most treatments have produced only slight to moderate benefit in less than half the patients treated.
C G, Goetz, H L, Klawans
+7 more sources
World Psychiatry, 2018 Tardive dyskinesia (TD) risk with D2/serotonin receptor antagonists or D2 receptor partial agonists (second‐generation antipsychotics, SGAs) is considered significantly lower than with D2 antagonists (first‐generation antipsychotics, FGAs).
Maren Carbon +2 more
exaly +2 more sources
Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review
Journal of Psychopharmacology, 2019Background: It is commonly recommended that a switch to clozapine be implemented in the face of tardive dyskinesia, even if current treatment involves another “atypical” agent.
Parnian Pardis, Ofer Agid
exaly +2 more sources
Treatment of Tardive Dyskinesia.
Neurologic clinics, 2020Tardive dyskinesia (TD) is an iatrogenic condition that encompasses a wide phenomenological spectrum of movement disorders caused by exposure to dopamine receptor blocking agents (DRBAs). TD may cause troublesome or disabling symptoms that impair quality
H. Bashir, J. Jankovic
semanticscholar +1 more source
Seminars in Neurology, 2007
This article provides up-to-date information regarding clinical manifestations, pathophysiology, and evidence-based treatment for tardive dyskinesia (TD). We conducted a comprehensive literature search, including sources such as the Cochrane Library, EMBASE, and Medline; and we manually searched bibliographic references.
Karla, Soares-Weiser +1 more
openaire +2 more sources
This article provides up-to-date information regarding clinical manifestations, pathophysiology, and evidence-based treatment for tardive dyskinesia (TD). We conducted a comprehensive literature search, including sources such as the Cochrane Library, EMBASE, and Medline; and we manually searched bibliographic references.
Karla, Soares-Weiser +1 more
openaire +2 more sources
Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited
Neurogastroenterology and Motility, 2019Metoclopramide is primarily a dopamine receptor antagonist, with 5HT3 receptor antagonist and 5HT4 receptor agonist activity, and used as an antiemetic and gastroprokinetic since almost 50 years.
A. Al-Saffar +2 more
semanticscholar +1 more source
Tardive dyskinesia: Who gets it and why.
Parkinsonism & Related Disorders, 2019Tardive dyskinesia (TD) is a potentially permanent movement disorder resulting from chronic use of dopamine receptor blocking agents (DRBA). Identified risk factors include the type of antipsychotic agent, being greater for those of first generation ...
K. Frei
semanticscholar +1 more source